Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Few data evaluated severe buccodental adverse events. The aim of this study was to evaluate sunitinib buccodental toxicity in patients with metastatic RCC and to compare it with that of sta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gilabert, M, Provansal, M, Cappiello, M, Walz, Y, Salem, N, Tarpin, C, Brunelle, S, Thomassin, J, Gravis, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790170/
https://ncbi.nlm.nih.gov/pubmed/24045668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.516
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados